Table 3.
Progression-free survival and overall survival relationships with categorical data.
| PFS | OS | |||||
|---|---|---|---|---|---|---|
| Mean | Median | p-value | Mean | Median | p-value | |
| Age – <65 years – ≥65 years |
36.2 15.8 |
21.7 13.3 |
0.006 |
46.4 22.5 |
58.3 14.4 |
0.002 |
| Sex – Women – Men |
31.6 25.7 |
18.0 16.6 |
0.332 |
39.1 33.5 |
31.7 21.7 |
0.540 |
| ECOG – 1 – 2 |
31.3 25.5 |
17.9 17.6 |
0.763 |
35.3 37.7 |
21.7 23.4 |
0.592 |
| Smoking – No – Yes |
34.9 20.4 |
22.4 14.0 |
0.036 |
40.0 31.5 |
31.7 21.7 |
0.463 |
| Comorbidity – No – Yes |
29.6 27.9 |
17.9 12.1 |
0.707 |
38.6 31.5 |
27.1 21.6 |
0.563 |
| Mutation – EGFR – ALK |
21.1 39.0 |
13.3 25.9 |
0.371 |
27.4 48.5 |
18.0 46.4 |
0.211 |
| Which series – First line – Second line and after |
32.3 24.4 |
18.0 17.5 |
0.478 |
40.1 33.1 |
46.4 23.0 |
0.580 |
| Metastasis site in diagnosis – Lung – Brain – Bone |
44.2 19.1 25.3 |
48.8 17.5 13.4 |
0.083 |
51.4 33.2 27.9 |
59.6 27.1 19.3 |
0.136 |
| Brain metastases on follow-up – No – Yes |
31.8 21.6 |
21.7 13.4 |
0.117 |
37.8 33.8 |
27.1 19.4 |
0.688 |
| NLR – <2.57 – ≥2.57 |
46.2 19.9 |
48.8 13.4 |
0.002 |
51.8 28.5 |
59.5 19.3 |
0.013 |
| PNI – <37.7 – ≥37.7 |
23.3 34.5 |
17.5 31.4 |
0.216 |
33.2 40.2 |
21.7 40.1 |
0.500 |
| SII – <799.5 – ≥799.5 |
45.6 20.1 |
48.8 13.4 |
0.003 |
48.3 29.5 |
59.5 19.4 |
0.042 |
| Neutrophil – <5.2 – ≥5.2 |
40.7 21.3 |
23.0 14.5 |
0.024 |
46.4 30.1 |
37.5 21.6 |
0.078 |
| Lymphocyte – <2.03 – ≥2.03 |
17.6 43.1 |
13.3 48.8 |
0.001 |
27.0 47.8 |
18 49.9 |
0.025 |
Bold p-values indicate they are statistically significant.
ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil–lymphocyte ratio; OS: Overall survival; PFS: Progression-free survival; PNI: Prognostic nutritional index; SII: Systemic immune-inflammation index.